Search Result

Results for "

Axl inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TAM Receptor (56) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (10) Autophagy (1) c-Fms (2) c-Kit (6) c-Met/HGFR (20) Discoidin Domain Receptor (4) E1/E2/E3 Enzyme (1) FGFR (1) FLT3 (16) HIF/HIF Prolyl-Hydroxylase (2) IGF-1R (2) Isotope-Labeled Compounds (1) PDGFR (1) ROS Kinase (2) Trk Receptor (4) VEGFR (11) VSV (1) YAP (3)
By Research Areas:	Cancer (71) Cardiovascular Disease (2) Endocrinology (2) Infection (2) Inflammation/Immunology (8) Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: TAM Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144708

Axl-IN-4

TAM Receptor Cancer

Axl-IN-4 (Compound 24) is an AXL kinase inhibitor with an IC₅₀ of 28.8 μM .
HY-144706

Axl-IN-3

TAM Receptor Cancer

Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC₅₀ of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .

Axl-IN-4	TAM Receptor	Cancer
Axl-IN-4 (Compound 24) is an AXL kinase inhibitor with an IC₅₀ of 28.8 μM .

Axl-IN-3	TAM Receptor	Cancer
Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC₅₀ of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .

HY-149491

HIV-IN-7	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Others
Axl-IN-16 (Compound 4) is a *Axl* inhibitor. Axl-IN-16 inhibits *Axl* expression and inhibits the activity of HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 can be isolated from“fruiting liquid (FL)” of Hypholoma lateritium and Hericium erinaceus .

HY-N12041

Axl-IN-16	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Cancer
Axl-IN-16 is a dual inhibitor of *Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits* hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-155310

AF-2112

YAP Cancer

AF-2112 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2.

AF-2112	YAP	Cancer
AF-2112 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2.

HY-155309

LM-41	YAP	Cancer
LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells .

HY-152075

AXL-IN-14	TAM Receptor	Cancer
AXL-IN-14 is a potent and orally active *AXL* inhibitor with an IC₅₀ value of 0.8 nM. AXL-IN-14 inhibits Gas6/AXL-mediated cell migration and invasion. AXL-IN-14 decreases the expression of p-AXL and p-AKT proteins. AXL-IN-14 shows anti-tumor activity .

HY-146596

Axl-IN-5

TAM Receptor Cancer

Axl-IN-5 (compound 1) is a AXL inhibitor with an IC₅₀ of 283 nM. Axl-IN-5 has anticancer effects .
HY-153441

AXL-IN-15

TAM Receptor Cancer

AXL-IN-15 (cpd391) is a potent Axl inhibitor with both K_i and IC₅₀ <1 nM. AXL-IN-15 can be used for research in cancer .
HY-162085

Axl-IN-17

TAM Receptor Cancer

Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC₅₀ value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .

Axl-IN-5	TAM Receptor	Cancer
Axl-IN-5 (compound 1) is a *AXL* inhibitor with an IC₅₀ of 283 nM. Axl-IN-5 has anticancer effects .

AXL-IN-15	TAM Receptor	Cancer
AXL-IN-15 (cpd391) is a potent *Axl* inhibitor with both K_i and IC₅₀ <1 nM. AXL-IN-15 can be used for research in cancer .

Axl-IN-17	TAM Receptor	Cancer
Axl-IN-17 (compound 13c) is an orally active, selective *AXL* inhibitor with an IC₅₀ value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .

HY-162103

Axl-IN-18	TAM Receptor Apoptosis	Cancer
Axl-IN-18 (compound 25c) is a potent and selective type II *AXL* inhibitor. Axl-IN-18 shows excellent AXL inhibitory activity (IC₅₀=1.1 nM) and 343-fold selectivity over the highly homologous kinase MET in biochemical assays (IC₅₀=377 nM). Axl-IN-18 significantly inhibits AXL-driven cell proliferation, dose-dependently suppresses 4T1 cell migration and invasion, and induces apoptosis. Axl-IN-18 shows noticeable antitumor efficacy in a BaF3/TEL-AXL xenograft model .

HY-146615

Axl-IN-6	TAM Receptor	Cancer
Axl-IN-6 (compound 14) is an orally active and potent *AXL* inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model .

HY-153012

Axl/Mer/CSF1R-IN-1

TAM Receptor c-Fms Cancer

Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with K_ds of <0.1 μM .

Axl/Mer/CSF1R-IN-1	TAM Receptor c-Fms	Cancer
Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with K_ds of <0.1 μM .

HY-147575

Axl-IN-8	TAM Receptor c-Met/HGFR	Cancer
Axl-IN-8 (NO.1) is a potent *AXL* inhibitor, with an IC₅₀ of <1 nM. Axl-IN-8 also inhibits c-MET, with an IC₅₀ of 1-10 nM. Axl-IN-8 shows anti-proliferative activity against BaF3/TEL-AXL, MKN45, and EBC-1 cells, with IC₅₀ values of <10, 226.6 and 120.3 nM, respectively .

HY-147577

Axl-IN-10	TAM Receptor	Inflammation/Immunology Cancer
Axl-IN-10 (Example 1) is a potent *AXL* inhibitor, with an IC₅₀ of 5 nM. Axl-IN-10 has excellent transmembrane properties.Axl-IN-10 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-10 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .

HY-147576

Axl-IN-9	TAM Receptor	Inflammation/Immunology Cancer
Axl-IN-9 (Example 10) is a potent *AXL* inhibitor, with an IC₅₀ of 26 nM. Axl-IN-9 has excellent transmembrane properties. Axl-IN-9 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-9 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .

HY-147574

Axl-IN-7	TAM Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Axl-IN-7 (Chemie 22) is a potent *AXL* inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease .

HY-P99161

Tilvestamab BGB149	TAM Receptor	Cancer
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks *AXL*-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced *AXL* activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in *AXL* overexpressing renal cell carcinomas .

HY-151904

AXL-IN-13	TAM Receptor FLT3 PDGFR	Cancer
AXL-IN-13 is a potent and orally active *AXL* inhibitor (IC₅₀: 1.6 nM, K_d: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .

HY-12494

LDC1267 5+ Cited Publications	TAM Receptor	Inflammation/Immunology Cancer
LDC1267 is a highly selective *TAM (Tyro3, Axl* and Mer)** kinase inhibitor with IC₅₀s of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively .

HY-153277

Axl/Mer/CSF1R-IN-2

TAM Receptor c-Fms Neurological Disease

Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor .

Axl/Mer/CSF1R-IN-2	TAM Receptor c-Fms	Neurological Disease
Axl/Mer/CSF1R-IN-2 (Comp 4) is a *Axl, Mer* and CSF1R inhibitor .

HY-147578

Axl-IN-11	TAM Receptor	Infection Inflammation/Immunology Cancer
Axl-IN-11 (Example 1) is a potent *AXL* inhibitor. Axl-IN-11 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .

HY-147579

Axl-IN-12	TAM Receptor	Infection Inflammation/Immunology Cancer
Axl-IN-12 (Example 2) is a potent *AXL* inhibitor. Axl-IN-12 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .

HY-15494S1

Picropodophyllin-d6 Axl1717-d₆; Picropodophyllotoxin-d₆; PPP-d₆	Isotope-Labeled Compounds IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-12432A

Gilteritinib hemifumarate 20+ Cited Publications ASP2215 hemifumarate	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

HY-12432

Gilteritinib 20+ Cited Publications ASP2215	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-150041

TL4830031	TAM Receptor	Cancer
TL4830031 (compound 8i), a quinolone antibiotic derivatives, is a potent *Axl* inhibitor with an IC₅₀ value of 26 nM. TL4830031 inhibits the phosphorylation of Axl. TL4830031 inhibits cell invasion and migration. TL4830031 can be used for cancer research .

HY-149092

Anticancer agent 109	TAM Receptor	Cancer
Anticancer agent 109 (compound 6-15) is an inhibitor of the *Gas6-Axl* axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models .

HY-15150

Bemcentinib

35+ Cited Publications

R428; BGB324
TAM Receptor Cancer

Bemcentinib (R428) is a potent and selective inhibitor of Axl with an IC₅₀ of 14 nM .

Bemcentinib 35+ Cited Publications R428; BGB324	TAM Receptor	Cancer
Bemcentinib (R428) is a potent and selective inhibitor of *Axl* with an IC₅₀ of 14 nM .

HY-12432S1

Gilteritinib-d8 ASP2215-d₈	FLT3 TAM Receptor	Cancer
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)
TAM Receptor Cancer

Bemcentinib (R428) GMP is an orally active and selective inhibitor of Axl with an IC₅₀ of 14 nM .

Bemcentinib (GMP) R428 (GMP); BGB324 (GMP)	TAM Receptor	Cancer
Bemcentinib (R428) GMP is an orally active and selective inhibitor of *Axl* with an IC₅₀ of 14 nM .

HY-12963

Dubermatinib 5+ Cited Publications TP-0903	TAM Receptor Apoptosis	Cancer
Dubermatinib (TP-0903) is a potent and selective *Axl* receptor tyrosine kinase inhibitor with an IC₅₀ value of 27 nM.

HY-100509

NPS-1034

1 Publications Verification

TAM Receptor c-Met/HGFR Apoptosis Cancer

NPS-1034 is a dual inhibitor of AXL and MET with IC₅₀s of 10.3 and 48 nM, respectively.

NPS-1034 1 Publications Verification	TAM Receptor c-Met/HGFR Apoptosis	Cancer
NPS-1034 is a dual inhibitor of *AXL* and MET with IC₅₀s of 10.3 and 48 nM, respectively.

HY-162406

UNC8969	Others	Cancer
UNC8969 (compound 43) is a *MERTK/AXL* dual inhibitor with IC₅₀s of 1.1±0.8 nM for MERTK and 5.3 ± 2.7 nM for AXL. UNC8969 also exerts a T_1/2 of 7.3 h with 5 mg/kg i.v. in mice .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific **AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6** and inhibits the interaction of GAS6 with *AXL, thereby substantially reducing AXL* signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-100946

CEP-40783

RXDX-106
TAM Receptor c-Met/HGFR Cancer

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC₅₀ values of 7 nM and 12 nM, respectively.
HY-132893

AZ14145845

TAM Receptor Cancer

AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.
HY-12965

S49076

1 Publications Verification

FGFR c-Met/HGFR Cancer

S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC₅₀ values below 20 nM.

CEP-40783 RXDX-106	TAM Receptor c-Met/HGFR	Cancer
CEP-40783 is a potent, selective and orally available inhibitor of *AXL* and c-Met with IC₅₀ values of 7 nM and 12 nM, respectively.

AZ14145845	TAM Receptor	Cancer
AZ14145845 is a highly selective type I1/2 dual *Mer/Axl* kinase inhibitor with in vivo efficacy.

S49076 1 Publications Verification	FGFR c-Met/HGFR	Cancer
S49076 is a novel, potent inhibitor of MET, *AXL/MER, and FGFR1/2/3* with IC₅₀ values below 20 nM.

HY-P99360

Enapotamab Anti-Axl/UFO Reference Antibody (enapotamab)	TAM Receptor	Cancer
Enapotamab is an *anti-AXL/UFO* reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .

HY-15494

Picropodophyllin 15+ Cited Publications Axl1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-114166

2-D08 4 Publications Verification	E1/E2/E3 Enzyme TAM Receptor	Cancer
2-D08 is a cell permeable, mechanistically unique inhibitor of protein SUMOylation. 2-D08 also inhibits *Axl* with an IC₅₀ of 0.49 nM.

HY-12964

SGI-7079 3 Publications Verification	TAM Receptor	Cancer
SGI-7079 is a potent and ATP-competitive *Axl* inhibitor, significantly inhibits the proliferation of SUM149 or KPL-4 cells with an IC₅₀ of 0.43 or 0.16 μM, respectively.

HY-114358

Tamnorzatinib ONO-7475	TAM Receptor Trk Receptor	Cancer
Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).

HY-15797

UNC2250 1 Publications Verification	TAM Receptor	Cancer
UNC2250 is a potent and selective Mer inhibitor with an IC₅₀ of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.

HY-107145

Ningetinib Tosylate	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and *Axl*, respectively.

HY-107145A

Ningetinib	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and *Axl*, respectively.

HY-104075

R916562	TAM Receptor VEGFR	Cancer
R916562 is an orally active and selective *Axl/VEGF-R2* inhibitor with IC₅₀s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis .

HY-124502

UNC4203	TAM Receptor FLT3	Cancer
UNC4203 is a potent, orally available and highly selective MERTK inhibitor, with IC₅₀s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively .

HY-125510

UNC2541 1 Publications Verification	TAM Receptor	Others
UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC₅₀ of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC₅₀, 510 nM) .

HY-147218

PF-07265807	c-Met/HGFR TAM Receptor	Cancer
PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC₅₀ values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15494

Picropodophyllin 15+ Cited Publications Axl1717; Picropodophyllotoxin; PPP	Structural Classification Classification of Application Fields Source classification Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Disease Research Fields Endocrinology	IGF-1R Apoptosis
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-N12041

Axl-IN-16	Structural Classification Natural Products Microorganisms Source classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of *Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits* hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-N3634

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	Others
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

Cat. No.	Product Name	Chemical Structure

HY-12432S1

Gilteritinib-d8

Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-15494S1

Picropodophyllin-d6
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Axl inhibitor

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products